Overview
Revolution Medicines, Inc., based in the United States, operates within the biotechnology industry, specifically focusing on developing novel therapies to inhibit frontier cancer targets within notorious cancer pathways. The company's innovative platform is designed to generate small molecules that are tailored to counter elusive, high-value RAS(ON) and mTOR pathway targets. Key projects include advancing a diverse pipeline of drugs aimed at multi-faceted anti-tumor activities. This includes efforts targeting specific mutations and dependencies in RAS and mTOR signaling networks, critical drivers of cancer cells' growth and survival. Revolution Medicines' strategic approach combines deep scientific and clinical development expertise to address the complex challenges presented by these cancer biology areas.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for Revolution Medicines, Inc. as of June 30, 2025 is -897.50 MM.
- The net income for Revolution Medicines, Inc. as of June 30, 2025 is -812.06 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | -897.50 | -812.06 | |
| 2025-03-31 | -789.42 | -697.51 | |
| 2024-12-31 | -689.52 | -600.09 | |
| 2024-09-30 | 0.74 | -627.70 | -567.06 |
| 2024-06-30 | 0.74 | -575.23 | -519.21 |
| 2024-03-31 | 4.57 | -527.39 | -484.27 |
| 2023-12-31 | 11.58 | -461.69 | -436.37 |
| 2023-09-30 | 26.17 | -368.91 | -331.34 |
| 2023-06-30 | 29.52 | -322.19 | -296.23 |
| 2023-03-31 | 34.82 | -275.49 | -259.16 |
| 2022-12-31 | 35.38 | -258.28 | -248.71 |
| 2022-09-30 | 29.51 | -249.49 | -244.87 |
| 2022-06-30 | 27.25 | -226.12 | -224.49 |
| 2022-03-31 | 26.84 | -208.56 | -207.56 |
| 2021-12-31 | 29.39 | -188.01 | -187.09 |
| 2021-09-30 | 28.68 | -169.18 | -168.62 |
| 2021-06-30 | 40.24 | -143.56 | -142.90 |
| 2021-03-31 | 41.57 | -127.01 | -125.82 |
| 2020-12-31 | 42.98 | -110.70 | -108.16 |
| 2020-09-30 | 46.32 | -96.18 | -88.55 |
Income Statement: EPS
- The earnings per share basic for Revolution Medicines, Inc. as of June 30, 2025 is -4.53.
- The earnings per share diluted for Revolution Medicines, Inc. as of June 30, 2025 is -4.53.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | -4.53 | -4.53 |
| 2025-03-31 | -4.02 | -4.02 |
| 2024-12-31 | -3.58 | |
| 2024-09-30 | -3.55 | -3.55 |
| 2024-06-30 | -3.58 | -3.58 |
| 2024-03-31 | -3.71 | -3.71 |
| 2023-12-31 | -3.86 | |
| 2023-09-30 | -3.31 | -3.31 |
| 2023-06-30 | -3.15 | -3.15 |
| 2023-03-31 | -3.02 | -3.02 |
| 2022-12-31 | -3.08 | |
| 2022-09-30 | -3.19 | -3.19 |
| 2022-06-30 | -3.04 | -3.04 |
| 2022-03-31 | -2.81 | -2.81 |
| 2021-12-31 | -2.57 | |
| 2021-09-30 | -2.38 | -2.38 |
| 2021-06-30 | -2.08 | -2.08 |
| 2021-03-31 | -1.93 | -1.93 |
| 2020-12-31 | -2.01 | |
| 2020-09-30 | -2.44 | -2.44 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Revolution Medicines, Inc. as of June 30, 2025 is -684.90 MM.
- The cash from investing activities for Revolution Medicines, Inc. as of June 30, 2025 is -396.05 MM.
- The cash from financing activities for Revolution Medicines, Inc. as of June 30, 2025 is 1,208.56 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -684.90 | -396.05 | 1,208.56 |
| 2025-03-31 | -591.31 | -322.38 | 959.48 |
| 2024-12-31 | -557.44 | -554.39 | 959.41 |
| 2024-09-30 | -539.71 | -541.89 | 924.96 |
| 2024-06-30 | -509.79 | -443.07 | 848.68 |
| 2024-03-31 | -448.74 | -594.56 | 905.80 |
| 2023-12-31 | -350.57 | -342.60 | 1,229.20 |
| 2023-09-30 | -291.80 | 30.70 | 441.21 |
| 2023-06-30 | -243.04 | -170.09 | 688.53 |
| 2023-03-31 | -231.63 | -64.14 | 625.33 |
| 2022-12-31 | -224.40 | -24.12 | 301.43 |
| 2022-09-30 | -201.88 | -8.48 | 260.80 |
| 2022-06-30 | -186.73 | 84.78 | 12.78 |
| 2022-03-31 | -165.09 | -100.40 | 12.22 |
| 2021-12-31 | -147.18 | -142.12 | 294.18 |
| 2021-09-30 | -132.95 | -87.70 | 284.94 |
| 2021-06-30 | -123.38 | -158.49 | 453.50 |
| 2021-03-31 | -109.29 | -172.21 | 451.30 |
| 2020-12-31 | -100.06 | -234.23 | 422.78 |
| 2020-09-30 | -86.68 | -289.16 | 419.76 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 | ||
| 2020-09-30 |
Management Effectiveness
- The roa for Revolution Medicines, Inc. as of June 30, 2025 is -0.39.
- The roe for Revolution Medicines, Inc. as of June 30, 2025 is -0.50.
- The roic for Revolution Medicines, Inc. as of June 30, 2025 is -0.32.
- The croic for Revolution Medicines, Inc. as of June 30, 2025 is 0.02.
- The ocroic for Revolution Medicines, Inc. as of June 30, 2025 is -0.27.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.39 | -0.50 | -0.32 | 0.02 | -0.27 |
| 2025-03-31 | -0.37 | -0.40 | -0.32 | 0.02 | -0.27 |
| 2024-12-31 | -0.58 | -0.68 | -0.34 | -0.09 | -0.33 |
| 2024-09-30 | -0.58 | -0.68 | -0.34 | -0.09 | -0.33 |
| 2024-06-30 | -0.45 | -0.51 | -0.27 | -0.08 | -0.25 |
| 2024-03-31 | -0.54 | -0.64 | -0.23 | 0.28 | -0.18 |
| 2023-12-31 | -0.40 | -0.49 | -0.37 | 0.20 | -0.32 |
| 2023-09-30 | -0.47 | -0.59 | -0.30 | 0.28 | -0.24 |
| 2023-06-30 | -0.47 | -0.59 | -0.30 | 0.28 | -0.24 |
| 2023-03-31 | -0.38 | -0.47 | -0.26 | 0.32 | -0.23 |
| 2022-12-31 | -0.33 | -0.38 | -0.33 | 0.07 | -0.27 |
| 2022-09-30 | -0.33 | -0.38 | -0.33 | 0.07 | -0.27 |
| 2022-06-30 | -0.29 | -0.33 | -0.40 | -0.16 | -0.33 |
| 2022-03-31 | -0.26 | -0.29 | -0.34 | -0.41 | -0.27 |
| 2021-12-31 | -0.33 | -0.39 | -0.28 | 0.01 | -0.22 |
| 2021-09-30 | -0.28 | -0.33 | -0.25 | 0.10 | -0.20 |
| 2021-06-30 | -0.31 | -0.40 | -0.20 | 0.24 | -0.17 |
| 2021-03-31 | -0.28 | -0.33 | -0.17 | 0.23 | -0.14 |
| 2020-12-31 | -0.49 | -0.71 | -0.21 | 0.17 | -0.20 |
| 2020-09-30 | -0.38 | -0.53 | -0.16 | 0.08 | -0.16 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | |||
| 2025-03-31 | -915.38 | -940.04 | -1,063.92 |
| 2024-12-31 | -727.72 | -764.23 | -845.95 |
| 2024-09-30 | -727.72 | -764.23 | -845.95 |
| 2024-06-30 | -99.81 | -106.06 | -115.50 |
| 2024-03-31 | -34.51 | -37.68 | -39.87 |
| 2023-12-31 | -12.02 | -12.66 | -14.10 |
| 2023-09-30 | -9.25 | -10.03 | -10.91 |
| 2023-06-30 | -9.25 | -10.03 | -10.91 |
| 2023-03-31 | -6.63 | -7.44 | -7.91 |
| 2022-12-31 | -7.15 | -8.30 | -8.45 |
| 2022-09-30 | -7.15 | -8.30 | -8.45 |
| 2022-06-30 | -6.99 | -8.24 | -8.30 |
| 2022-03-31 | -6.55 | -7.73 | -7.77 |
| 2021-12-31 | -5.36 | -6.37 | -6.40 |
| 2021-09-30 | -4.94 | -5.88 | -5.90 |
| 2021-06-30 | -2.94 | -3.55 | -3.57 |
| 2021-03-31 | -2.50 | -3.03 | -3.06 |
| 2020-12-31 | -2.08 | -2.52 | -2.58 |
| 2020-09-30 | -1.65 | -1.91 | -2.08 |
Identifiers and Descriptors
| Central Index Key (CIK) | 1628171 |
